The screening kits were developed using miRNAs for high-risk populations for urothelial carcinoma (UC). Products 702703 are designed for chronic kidney diseasehemodialysis patients using urineblood samples, respectively. With high accuracyminimal invasiveness, the kits are intended to be used as a screeningregular monitoring of UC. If a test reveals a positive result, the patient then undergoes cystoscopic examination for further confirmation. Otherwise, the patent only needs to be monitored annually.